Labiotech.eu

News and Trends 17 Oct 2022

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30, a cytokine that may perform immunomodulatory functions, promotes prostate cancer onset and development, but whether it can be a suitable therapeutic target remains to be investigated. In a new study published in the Journal of Hematology & Oncology, researchers at […]

October 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

PerkinElmer’s Horizon Discovery: the lowdown on base editing

PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and development. Horizon’s portfolio is focused on research reagents; screening and cell line engineering services; bioproduction cell lines; reference standards and base editing. Horizon’s base editing platform, Pin-point is a gene editing method with the ability to effect multiple single base edits […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

The challenges of translating CRISPR to the clinic

CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of disease processes, and for the development of ground-breaking genetic medicines. As these new classes of cell and gene therapies translate to the clinical setting, some key bottlenecks remain to be solved before the technology will realize its full societal impact. […]

October 17, 2022 - 6 minutesmins - By Jim Cornall

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 17 Oct 2022

CRISPR/Cas9: Challenges and outlook from an investor’s perspective

A Q&A with Fady Riad, CEO of consulting company Centurion Life Sciences. How did CRISPR/Cas9 revolutionize gene editing and the broader life sciences industry? CRISPR/Cas9 is undoubtedly one of the greatest scientific advancements of the last 100 years. In 2012, Jennifer Doudna and Emanuelle Charpentier published a peer-reviewed paper discussing the use of CRISPR/Cas9 in […]

October 17, 2022 - 6 minutesmins - By External Contributor

More News! 14 Oct 2022

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Oct 2022

Cytel signs agreement with two Scandinavian medicinal product companies

U.S.-based Cytel Inc. has entered into an agreement to acquire Scandinavian companies SDS Life Sciences AB and SDS MedeQ AB. Cytel says the move will add new talent to the company’s strategic consulting group and bring additional capabilities for the development of drugs and medical devices. It says sponsors will also have easier access to […]

October 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 14 Oct 2022

Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals

This week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas Turner, CEO and co-founder of Cultivated Biosciences; and Joanna Magaji, conference manager for the BiotechX event. BiotechX event taking place in Basel in November BiotechX, […]

October 14, 2022

News and Trends 14 Oct 2022

Danish researchers create ‘Wikipedia of resistant bacteria’

According to the WHO, antibiotic resistance is one of the biggest threats to public health. Researchers at DTU in Denmark have created a new tool in the fight against resistant bacteria that, based on 214,000 microbiome samples, can create an overview of the problem across countries, people and environments. In the future, even a small […]

October 14, 2022 - 4 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 14 Oct 2022

Mablink Bioscience receives €31M series A funding for ADC pipeline

French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody drug conjugates (ADCs). The round was led by Sofinnova Partners and Mérieux Equity Partners. Existing shareholders Elaia Partners, UI-Investissement/Pertinence Invest 2 (advised by Mérieux Equity […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Oct 2022

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Plan launched to improve diversity of clinical trials

Help to improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age and ethnicity has been revealed. Medidata, a Dassault Systèmes company, has launched the intelligent trials diversity module. The new module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites […]

October 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

Agreement to take advantage of stem cells from first teeth

An agreement has been made to utilize the advantage of stem cells from human exfoliated deciduous teeth (SHED) under development by Japan-based Kidswell Bio. Kidswell is entering into the agreement with Showa Denko Materials Co., which will also enable process development as well as clinical manufacturing of cell therapy products. Under the terms of agreement, […]

October 13, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

PerkinElmer’s Horizon Discovery: the lowdown on base editing

The challenges of translating CRISPR to the clinic

CRISPR/Cas9: Challenges and outlook from an investor’s perspective

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

Cytel signs agreement with two Scandinavian medicinal product companies

Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals

Danish researchers create ‘Wikipedia of resistant bacteria’

Mablink Bioscience receives €31M series A funding for ADC pipeline

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

Plan launched to improve diversity of clinical trials

Agreement to take advantage of stem cells from first teeth

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!